BIOREXIS
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
BIOREXIS
Industry:
Health Care Insurance Therapeutics
Founded:
2001-08-01
Address:
United, Pennsylvania, United States
Country:
United States
Total Employee:
1+
Status:
Active
Total Funding:
38 M USD
Current Advisors List
Founder
Investors List
Prism Venture Management
Prism Venture Management investment in Series B - BioRexis
Johnson & Johnson Development Corporation
Johnson & Johnson Development Corporation investment in Series B - BioRexis
Anthem Capital Management
Anthem Capital Management investment in Series B - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series B - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series B - BioRexis
Gund Investment, LLC
Gund Investment, LLC investment in Series B - BioRexis
ProQuest Investments
ProQuest Investments investment in Series A - BioRexis
Quaker BioVentures
Quaker BioVentures investment in Series A - BioRexis
Tullis Health Investors
Tullis Health Investors investment in Series A - BioRexis